Axsome Therapeutics to Participate in Investor Conferences in September

Axsome Therapeutics will participate in four upcoming investor conferences in September, including the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and Baird Global Healthcare Conference. The company will also participate in a virtual summit hosted by TD Cowen and investor meetings hosted by Deutsche Bank.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a leading biopharmaceutical company specializing in the treatment of central nervous system (CNS) disorders, has announced its participation in several upcoming investor conferences and events in September. The company will be present at the following conferences:

- Wells Fargo Healthcare Conference: The company will host a fireside chat on Wednesday, September 3, 2025, at 3:45 p.m. ET in Boston, MA.
- Cantor Global Healthcare Conference 2025: Axsome will participate in a fireside chat on Thursday, September 4, 2025, at 1:00 p.m. ET in New York, NY.
- Morgan Stanley 23rd Annual Global Healthcare Conference: The company will present at a fireside chat on Monday, September 8, 2025, at 2:35 p.m. ET in New York, NY.
- Baird 2025 Global Healthcare Conference: Axsome will host a fireside chat on Wednesday, September 10, 2025, at 3:10 p.m. ET in New York, NY.

Additionally, the company will participate in a virtual summit hosted by TD Cowen and investor meetings hosted by Deutsche Bank. Webcasts of the presentations at the Wells Fargo, Cantor, Morgan Stanley, and TD Cowen conferences will be available on the “Webcasts & Presentations” page of the “Investors” section of the company’s website at [axsome.com](http://axsome.com). Replays of the webcasts will be available for approximately 30 days following each event.

Axsome Therapeutics is a biopharmaceutical company focused on delivering scientific breakthroughs in CNS conditions. Their industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine. The company also has multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions.

The company’s participation in these events is an opportunity for investors and financial professionals to gain insights into its pipeline, clinical trials, and future prospects. It is also a chance for the company to engage with key stakeholders and discuss its mission to solve some of the brain’s biggest problems.

References:
[1] https://www.marketscreener.com/news/axsome-therapeutics-to-participate-in-upcoming-investor-conferences-ce7c50dedd88f02d
[2] https://www.globenewswire.com/news-release/2025/08/27/3139860/33090/en/Axsome-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html